Annovis Bio Inc. (NYSE: ANVS) plans to present three sessions at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, scheduled for Nov. 16-19, 2026, in Boston. The presentations will focus on the company's investigational oral therapy buntanetap, including its mechanism of action, the design of its pivotal Phase 3 study in early Alzheimer's disease, and the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer's drug candidates. The program features an oral presentation on Nov. 19 by Alexander Morin, director of strategic communications, and two poster presentations on Nov. 16-17, one of which will be given by Chief Scientific Officer Cheng Fang.
The presentations come as Annovis approaches a pivotal clinical data readout in early 2027 and prepares for a New Drug Application. Buntanetap is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients.
For investors and industry observers, the CTAD presentations offer visibility into the design and baseline characteristics of the Phase 3 trial, which could influence expectations ahead of the data readout. The inclusion of AI-driven blood-brain barrier permeability predictions also signals the company's broader interest in applying computational tools to drug development, potentially affecting how late-stage Alzheimer's candidates are evaluated. Annovis is headquartered in Malvern, Pennsylvania, and is a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. More information is available at www.annovisbio.com. The company also maintains a presence on LinkedIn, YouTube, and X. The latest news and updates relating to ANVS are available in the company's newsroom at https://nnw.fm/ANVS. The full press release can be viewed at https://nnw.fm/2k4SQ.
The announcement was distributed by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NNW is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, which provides wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For readers, the key takeaway is that Annovis is advancing a late-stage Alzheimer's candidate with a novel mechanism, and the upcoming CTAD presentations and 2027 data readout could shape the treatment landscape and investment thesis in neurodegenerative disease research.
